CO5271650A1 - Peptidos modificados y peptidomimeticos para el uso en inmunoterapia - Google Patents

Peptidos modificados y peptidomimeticos para el uso en inmunoterapia

Info

Publication number
CO5271650A1
CO5271650A1 CO00079334A CO00079334A CO5271650A1 CO 5271650 A1 CO5271650 A1 CO 5271650A1 CO 00079334 A CO00079334 A CO 00079334A CO 00079334 A CO00079334 A CO 00079334A CO 5271650 A1 CO5271650 A1 CO 5271650A1
Authority
CO
Colombia
Prior art keywords
amino acids
formula
substitution
ser
modified
Prior art date
Application number
CO00079334A
Other languages
English (en)
Inventor
Staveren Catherina Joanna Van
Timmers Cornelis Marius
Johannes Marie Van Galen Philippus
Ronald Marce Alphonsus Knegtel
Boots Anna Maria Helena
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of CO5271650A1 publication Critical patent/CO5271650A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un péptido modificado derivado de H-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH (fórmula I) que tiene la fórmula general Q-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-Z (fórmula II), donde A1 a A13 corresponden a los amino ácidos de la fórmula I, Q corresponde a H y Z corresponde a OH, CARACTERIZADO porque 1 a 6 modificaciones se seleccionan de uno o más de los grupos a, b ó c consistentes en: a) sustitución de 1-6, de preferencia 1-4 amino ácidos en A1 a A13 por amino ácidos no naturales o ß amino ácidos, b) sustitución de uno o más enlaces amida por enlaces amida reducidos o isoesteres de etileno, c) sustituciones en Q y / o Z: y opcionalmente d) sustitución por amino ácidos naturales hasta un total de 6 modificaciones.
CO00079334A 1999-10-18 2000-10-18 Peptidos modificados y peptidomimeticos para el uso en inmunoterapia CO5271650A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99203427 1999-10-18

Publications (1)

Publication Number Publication Date
CO5271650A1 true CO5271650A1 (es) 2003-04-30

Family

ID=8240756

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00079334A CO5271650A1 (es) 1999-10-18 2000-10-18 Peptidos modificados y peptidomimeticos para el uso en inmunoterapia

Country Status (23)

Country Link
EP (1) EP1226167A1 (es)
JP (1) JP2003512388A (es)
KR (1) KR20020047245A (es)
CN (1) CN1379786A (es)
AR (1) AR026068A1 (es)
AU (1) AU780238B2 (es)
BR (1) BR0014803A (es)
CA (1) CA2386398A1 (es)
CO (1) CO5271650A1 (es)
CZ (1) CZ20021356A3 (es)
HK (1) HK1046693A1 (es)
HU (1) HUP0203504A3 (es)
IL (1) IL148778A0 (es)
MX (1) MXPA02003520A (es)
NO (1) NO20021763D0 (es)
NZ (1) NZ518256A (es)
PE (1) PE20010692A1 (es)
PL (1) PL354590A1 (es)
RU (1) RU2002113107A (es)
SK (1) SK6842002A3 (es)
TR (1) TR200201036T2 (es)
WO (1) WO2001029081A1 (es)
ZA (1) ZA200202577B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951212A0 (en) * 2002-09-04 2002-09-19 Monash University A method of modulating cellular activity and molecules for use therein
EP2016054A2 (en) * 2006-04-06 2009-01-21 Purdue Research Foundation Derivatization-enhanced analysis of amino acids and peptides
EP2114462B1 (en) * 2006-12-21 2013-06-05 Universite De Geneve Compounds for fluorescence imaging
NZ586909A (en) 2008-01-23 2012-05-25 Herlev Hospital Ykl-40 as a general marker for non-specific disease
NZ592241A (en) 2008-09-15 2012-11-30 Herlev Hospital Ykl-40 as a marker for gastrointestinal cancers
US11014970B2 (en) 2014-11-07 2021-05-25 Kineta Chronic Pain, Llc Modifications and uses of conotoxin peptides
EP3466963A1 (en) * 2017-10-05 2019-04-10 Suigeneris Farmacosmetics, S.L. Anticancer peptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115744A (en) * 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
IL127332A0 (en) * 1996-06-07 1999-09-22 Zeneca Ltd Peptide derivatives
IL122233A (en) * 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them

Also Published As

Publication number Publication date
BR0014803A (pt) 2002-06-11
CN1379786A (zh) 2002-11-13
KR20020047245A (ko) 2002-06-21
SK6842002A3 (en) 2002-09-10
EP1226167A1 (en) 2002-07-31
JP2003512388A (ja) 2003-04-02
PE20010692A1 (es) 2001-07-06
NO20021763L (no) 2002-04-15
MXPA02003520A (es) 2002-08-20
TR200201036T2 (tr) 2002-08-21
AR026068A1 (es) 2002-12-26
AU780238B2 (en) 2005-03-10
NO20021763D0 (no) 2002-04-15
HUP0203504A3 (en) 2005-03-29
HK1046693A1 (zh) 2003-01-24
RU2002113107A (ru) 2004-01-10
WO2001029081A1 (en) 2001-04-26
CA2386398A1 (en) 2001-04-26
IL148778A0 (en) 2002-09-12
CZ20021356A3 (cs) 2002-07-17
AU1139601A (en) 2001-04-30
PL354590A1 (en) 2004-01-26
HUP0203504A2 (hu) 2003-04-28
ZA200202577B (en) 2003-09-23
NZ518256A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
ES2564463T3 (es) Péptidos antigénicos de Neisseriales
WO1998007745A3 (en) Compositions and methods for treating infections using analogues of indolicidin
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
AU2007325952A8 (en) Cell-free synthesis of proteins containing unnatural amino acids
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
HK1025103A1 (en) Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
SG162791A1 (en) Mucin hypersecretion inhibitors based on the structure of mans and methods of use
EP1548107A4 (en) CHROMOPROTEIN AND FLUOROPROTEINS
CO5271650A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
GB9914045D0 (en) Novel compounds
ATE385805T1 (de) Neue peptide
ES2557938T3 (es) Antagonistas de resistina y su uso
DK1504036T3 (da) Toxinrelaterede fragmenter af antistoffer med antimikrobiel og antiviral aktivitet
MY126118A (en) Somatostatin analogs for the treatment of cancer
ECSP003720A (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia
ATE291587T1 (de) Somatostatin analoge und deren verwendung zur behandlung von krebs
DE69834929D1 (de) Verwendung eines organspezifischen ernährungmittels
NZ511747A (en) Regulatory/unfolding peptides of ezrin
AR004497A1 (es) Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.
SE9700301D0 (sv) New compound

Legal Events

Date Code Title Description
FC Application refused